FDA Approves Ferring Pharmaceuticals' New Manufacturing Facility for Bladder Cancer Gene Therapy ADSTILADRIN
Key Insights
The FDA has approved Ferring Pharmaceuticals' new drug product manufacturing hub in Parsippany, NJ, for production of ADSTILADRIN, the first FDA-approved intravesical gene therapy for high-risk BCG-unresponsive bladder cancer (search).
The approval expands Ferring's manufacturing capabilities to three sites dedicated to ADSTILADRIN production, triggering a final $200 million payment from Royalty Pharma as part of a financing agreement announced in 2023.
The 12,000 square foot state-of-the-art facility features renewable energy solutions and specialized technology to ensure stable supply for growing global demand, reinforcing Ferring's commitment to uro-oncology treatment innovation.
Ferring Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for its new drug product manufacturing hub in Parsippany, New Jersey, dedicated to the production of ADSTILADRIN (nadofaragene firadenovec-vncg), a breakthrough gene therapy for bladder cancer (search).
The approval marks a significant expansion of Ferring's manufacturing capabilities, bringing the total to three cutting-edge sites focused on ADSTILADRIN production. This milestone also secures a final $200 million payment from Royalty Pharma as part of a royalty-based financing agreement announced in 2023.
"The FDA approval of our new manufacturing facility for ADSTILADRIN represents our unwavering dedication to delivering high-quality, innovative therapies at scale," said Armin Metzger, Executive Vice President, Chief Technical Operations Officer at Ferring Pharmaceuticals. "This expansion and diversification of our manufacturing footprint will further ensure stable and sustainable supply of ADSTILADRIN to meet the anticipated growth in global demand."
Strategic Manufacturing Expansion
Located on Ferring's U.S. campus in Parsippany, the new 12,000 square foot facility features a cutting-edge manufacturing suite fully integrated with specialized modern technology and equipment. The site incorporates renewable energy solutions, including waste heat recovery with heat pumps and solar energy, aligning with Ferring's environmental sustainability commitments.
The new facility joins existing manufacturing sites in Kuopio, Finland, creating a diversified production network that enhances supply chain resilience for this critical therapy.
Transformative Therapy for Bladder Cancer
ADSTILADRIN is the first and only intravesical non-replicating gene therapy approved by the FDA for patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (search) (NMIBC (search)) with carcinoma in situ (search) (CIS (search)) with or without papillary tumors.
"ADSTILADRIN has transformed the treatment landscape for BCG-unresponsive bladder cancer (search) patients and drives Ferring's continued growth in uro-oncology," said Bipin Dalmia, Global Head of Uro-Oncology and Urology Franchise at Ferring Pharmaceuticals. "The growing body of clinical evidence for ADSTILADRIN — including recently announced independent real-world data and data from our Japan Phase 3 trial — underscores the impact of this therapy."
Clinical Evidence and Mechanism of Action
ADSTILADRIN works through a novel mechanism, utilizing a non-replicating adenovirus vector containing the gene for interferon alfa-2b. Administered directly into the bladder via catheter once every three months, the therapy transforms bladder wall cells into "interferon microfactories," enhancing the body's natural defenses against cancer.
The pivotal Phase 3 study that led to FDA approval demonstrated that 51% of patients with CIS (search) with or without papillary tumors achieved a complete response by three months. More recent data from Japan shows even more promising results, with a 75% complete response rate at three months in a Phase 3 trial.
Independent real-world data presented by the Mayo Clinic further validates the therapy's effectiveness, showing a 79% complete response rate at three months in patients with CIS (search) with or without Ta/T1 tumors.
Addressing an Unmet Medical Need
Bladder cancer (search) is the sixth most commonly diagnosed cancer in the United States and the fourth most common among men. Approximately 84,870 new cases of bladder cancer are expected in the U.S. in 2025, with about 75% presenting as NMIBC (search).
For patients with high-risk NMIBC (search), BCG therapy has been the standard first-line treatment. However, approximately one-third of patients do not respond to BCG therapy, and 50% of initial responders experience disease recurrence or progression. Prior to ADSTILADRIN, treatment options for BCG-unresponsive patients were limited, with guidelines often recommending cystectomy (partial or complete removal of the bladder).
Patient Access and Availability
As of January 2024, ADSTILADRIN is fully available and accessible in the U.S., with 99% coverage confirmed for commercial and government-insured patients. Since establishing an Average Sales Price (ASP) with the Centers for Medicare and Medicaid Services (CMS) on April 1, 2024, all covered claims submitted for reimbursement have received payment within an average of 25 days.
The manufacturing expansion underscores Ferring's commitment to ensuring this innovative therapy reaches all eligible patients who could benefit from it, addressing a significant unmet need in bladder cancer (search) treatment.